| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Agios Pharmaceuticals, Inc. (AGIO) has 10 insiders with recent SEC Form 4 filings, including 0 buys and 37 sells. AGIO is classified in the Biotechnology industry within the Health Care sector.
| Role | Insider | Shares | Value | 30d |
|---|---|---|---|---|
| CEO | 149.1K | $5.27M | - | |
| Other | 67.7K | $2.39M | - | |
| CFO | 40.3K | $1.42M | - | |
| Other | 34.6K | $1.22M | - | |
| Dir | 17.8K | $629.1K | - |
Buys and sells only
| Date | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|
| Dec 7, 2017 | Cantley Lewis Clayton Jr. | Director | Sell | 3,838 | $59.37 | $227,856.81 | -0.5% | |
| Dec 1, 2017 | Schenkein David P59 | Chief Executive Officer | Sale+OE | 6,000 | $61.55 | $369,288.00 | -93.8% | |
| Dec 1, 2017 | Biller Scott | Chief Scientific Officer | Sale+OE | 2,146 | $60.79 | $130,458.98 | -9.3% | |
| Nov 14, 2017 | Cantley Lewis Clayton Jr. | Director | Sell | 4,000 | $60.88 | $243,539.80 | -0.8% | |
| Nov 1, 2017 | Schenkein David P59 | Chief Executive Officer | Sale+OE | 6,000 | $63.85 | $383,105.24 | -28.2% | |
| Nov 1, 2017 | Biller Scott | Chief Scientific Officer | Sale+OE | 2,146 | $62.69 | $134,522.26 | -6.7% | |
| Oct 17, 2017 | Cantley Lewis Clayton Jr. | Director | Sell | 4,000 | $71.10 | $284,380.00 | -1.2% | |
| Oct 4, 2017 | Schenkein David P59 | Chief Executive Officer | Sale+OE | 80,000 | $70.14 | $5,611,200.00 | -100% | |
| Oct 4, 2017 | Biller Scott | Chief Scientific Officer | Sell | 10,470 | $70.00 | $732,900.00 | -100% | |
| Oct 2, 2017 | Biller Scott | Chief Scientific Officer | Sale+OE | 2,146 | $67.23 | $144,275.58 | -14.6% |